PURPOSE: The aim of this study was to compare the effectiveness of prophylactic single fixed dose of pegfilgrastim and daily administration of filgrastim on febrile neutropenia (FN), severe neutropenia, treatment delay, and dose reduction in patients with breast cancer receiving dose-dense adjuvant chemotherapy. METHODS: A retrospective cohort study with 1058 breast cancer patients matched by age and chemotherapy was conducted. The primary endpoints were FN, severe (grade 3, 4) neutropenia, dose reduction (>10 % reduction of the dose planned), and treatment delay (dose given more than 2 days later). RESULTS: Eighteen episodes of FN (3.4%) in the filgrastim group and 23 (4.3%) in the pegfilgrastim group (p = 0.500) were recorded. More than half of the total episodes (27/41) occurred during the first 4 cycles of treatment. Patients who received filgrastim were almost three times more likely to experience a severe neutropenia episode and were significantly more likely to experience a dose reduction (18.5%) compared to those who received pegfilgrastim (10.8%) (p < 0.001). The percentage of patients, who received their planned dose on time, was significantly lower in patients receiving filgrastim (58%) compared to those receiving pegfilgrastim (72.4%, p < 0.001). CONCLUSIONS: No significant difference was detected on FN rate between daily administration of filgrastim and single administration of pegfilgrastim. However, patients receiving pegfilgrastim had a significantly lower rate of severe neutropenia, as well as dose reduction and treatment delay, thus, achieving a higher dose density.
PURPOSE: The aim of this study was to compare the effectiveness of prophylactic single fixed dose of pegfilgrastim and daily administration of filgrastim on febrile neutropenia (FN), severe neutropenia, treatment delay, and dose reduction in patients with breast cancer receiving dose-dense adjuvant chemotherapy. METHODS: A retrospective cohort study with 1058 breast cancerpatients matched by age and chemotherapy was conducted. The primary endpoints were FN, severe (grade 3, 4) neutropenia, dose reduction (>10 % reduction of the dose planned), and treatment delay (dose given more than 2 days later). RESULTS: Eighteen episodes of FN (3.4%) in the filgrastim group and 23 (4.3%) in the pegfilgrastim group (p = 0.500) were recorded. More than half of the total episodes (27/41) occurred during the first 4 cycles of treatment. Patients who received filgrastim were almost three times more likely to experience a severe neutropenia episode and were significantly more likely to experience a dose reduction (18.5%) compared to those who received pegfilgrastim (10.8%) (p < 0.001). The percentage of patients, who received their planned dose on time, was significantly lower in patients receiving filgrastim (58%) compared to those receiving pegfilgrastim (72.4%, p < 0.001). CONCLUSIONS: No significant difference was detected on FN rate between daily administration of filgrastim and single administration of pegfilgrastim. However, patients receiving pegfilgrastim had a significantly lower rate of severe neutropenia, as well as dose reduction and treatment delay, thus, achieving a higher dose density.
Authors: Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff Journal: J Clin Oncol Date: 2006-05-08 Impact factor: 44.544
Authors: F A Holmes; S E Jones; J O'Shaughnessy; S Vukelja; T George; M Savin; D Richards; J Glaspy; L Meza; G Cohen; M Dhami; D R Budman; J Hackett; M Brassard; B B Yang; B C Liang Journal: Ann Oncol Date: 2002-06 Impact factor: 32.976
Authors: G von Minckwitz; M Schwenkglenks; T Skacel; G H Lyman; A Lopez Pousa; P Bacon; V Easton; M S Aapro Journal: Eur J Cancer Date: 2008-12-26 Impact factor: 9.162
Authors: Gary H Lyman; Kim Allcott; Jacob Garcia; Scott Stryker; Yanli Li; Maureen T Reiner; Derek Weycker Journal: Support Care Cancer Date: 2017-05-08 Impact factor: 3.603
Authors: Isabel Puértolas; Alberto Frutos Pérez-Surio; María Aránzazu Alcácera; Raquel Andrés; María Del Tránsito Salvador Journal: Eur J Clin Pharmacol Date: 2017-11-19 Impact factor: 2.953
Authors: Yan Qin; Xiaohong Han; Lin Wang; Ping Du; Jiarui Yao; Di Wu; Yuanyuan Song; Shuxiang Zhang; Le Tang; Yuankai Shi Journal: Chin J Cancer Res Date: 2017-10 Impact factor: 5.087
Authors: Claudio Cerchione; Lucio Catalano; Ilaria Peluso; Davide Nappi; Maria Di Perna; Dalila Salvatore; Ilaria Migliaccio; Marco Picardi; Fabrizio Pane Journal: Support Care Cancer Date: 2016-10-10 Impact factor: 3.603
Authors: Paul Cornes; Pere Gascon; Stephen Chan; Khalid Hameed; Catherine R Mitchell; Polly Field; Mark Latymer; Luiz H Arantes Journal: Adv Ther Date: 2018-10-08 Impact factor: 3.845